Does Rallies track congressional trades in ELV?

Yes. Rallies tracks politician and congressional stock disclosures for ELV, including reported purchases, sales, dates, owners, and trade amounts when available.

Is ELV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ELV. It does not provide personalized investment advice.

ELV (Elevance Health) Stock Analysis - Politician Trades

Elevance Health (ELV) is a publicly traded Healthcare sector company. As of May 20, 2026, ELV trades at $394.13 with a market cap of $85.58B and a P/E ratio of 15.96. ELV moved -2.37% today. Year to date, ELV is +13.56%; over the trailing twelve months it is -0.38%. Its 52-week range spans $273.71 to $528.52. Analyst consensus is buy with an average price target of $387.47. Rallies surfaces ELV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded ELV stock?

Recent politician trading activity in ELV includes disclosures from Markwayne Mullin, John Fetterman, Lisa McClain, Lisa McClain, and Gilbert Cisneros. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

ELV Key Metrics

Key financial metrics for ELV
Metric	Value
Price	$394.13
Market Cap	$85.58B
P/E Ratio	15.96
EPS	$25.28
Dividend Yield	1.72%
52-Week High	$528.52
52-Week Low	$273.71
Volume	489.80K
Avg Volume	0
Revenue (TTM)	$199.13B
Net Income	$5.66B
Gross Margin	89.36%

Congressional Trades in ELV

Markwayne Mullin purchase ELV on Dec 29, 2025 (amount: $50.00K) for Joint.
John Fetterman sale ELV on Sep 19, 2025 (amount: $15.00K).
Lisa McClain sale ELV on Aug 13, 2025 (amount: $15.00K) for Spouse.
Lisa McClain purchase ELV on Jun 24, 2025 (amount: $15.00K) for Spouse.
Gilbert Cisneros sale ELV on May 30, 2025 (amount: $15.00K).

Latest ELV News

Elevance Health Buy Rating Boosts Target to $498 on 14.5x 2028 Earnings — May 20, 2026
Elevance Health jumps after BofA upgrade to Buy, $435 target on Medicaid margin recovery — Apr 29, 2026
Elevance Health jumps as Q1 beats expectations and management lifts 2026 outlook — Apr 27, 2026
Elevance Health jumps after Q1 beat and higher 2026 adjusted EPS outlook — Apr 23, 2026
Elevance slides despite Q1 beat as $935M CMS accrual sharpens regulatory overhang — Apr 22, 2026

Recent ELV Insider Trades

SCHULMAN AMY W sold 26 (~$7.47K) on Mar 12, 2026.
Kendrick Charles Morgan JR sold 3.20K (~$910.60K) on Mar 6, 2026.
COLLIS STEVEN H bought 3.00K (~$869.52K) on Mar 5, 2026.

ELV Analyst Consensus

16 analysts cover ELV: 0 strong buy, 11 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $387.47.

Common questions about ELV

Which politicians traded ELV stock?: Recent politician trading activity in ELV includes disclosures from Markwayne Mullin, John Fetterman, Lisa McClain, Lisa McClain, and Gilbert Cisneros. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in ELV?: Yes. Rallies tracks politician and congressional stock disclosures for ELV, including reported purchases, sales, dates, owners, and trade amounts when available.
Is ELV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ELV. It does not provide personalized investment advice.